BRCA Mutation clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
open to eligible people ages 18 years and up
This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of…
at UCSF
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Sorry, in progress, not accepting new patients
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
at UCLA
Our lead scientists for BRCA Mutation research studies include Pamela Munster, MD.
Last updated: